Compare PLUS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLUS | URGN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 1996 | 2016 |
| Metric | PLUS | URGN |
|---|---|---|
| Price | $95.07 | $25.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $60.71 |
| AVG Volume (30 Days) | 219.8K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | ★ 24.20 | N/A |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $2,442,549,000.00 | $1,128,000.00 |
| Revenue This Year | $4.67 | $190.44 |
| Revenue Next Year | $4.89 | $69.25 |
| P/E Ratio | $34.71 | ★ N/A |
| Revenue Growth | ★ 18.07 | N/A |
| 52 Week Low | $73.09 | $16.50 |
| 52 Week High | $98.21 | $50.81 |
| Indicator | PLUS | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 23.73 |
| Support Level | $85.87 | $18.28 |
| Resistance Level | $98.03 | $27.76 |
| Average True Range (ATR) | 4.31 | 2.07 |
| MACD | -0.13 | -0.72 |
| Stochastic Oscillator | 84.64 | 8.46 |
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.